Other hereditary or degenerative neurological disorders

This collection of diseases encompasses a wide range of conditions, categorised by their symptomatic impact upon the neurological system. Pathogenesis and epidemiology are

...


Read more on Other hereditary or degenerative neurological disorders

 

 

Latest news articles

Added 2 months ago Drug news

Novartis announces results of Phase I START trial for Zolgensma for spinal muscular atrophy type 1.

With FDA acceptance of the BLA for Zolgensma Novartis has announced details of the START trial. START was a Phase...

Added 2 months ago Drug news

FDA accepts BLA for Zolgensma, a gene replacement therapy to treat spinal muscular atrophy (SMA) Type 1. Novartis.

Novartis announced that the FDA has accepted the company's Biologics License Application (BLA) for AVXS-101, now known as Zolgensma (onasemnogene...

Added 4 months ago Drug news

AVXS 101 filed in the EU, US and Japan for spinal muscular atrophy.- AveXis.

AveXis announced it has submitted regulatory applications for AVXS 101 (gene therapy) in the U.S., Europe and Japan for use...

Search all news articles for Other hereditary or degenerative neurological disorders
 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Migraine Knowledge Centre

Migraine Knowledge Centre

The Migraine Knowledge Centre features latest research on the prevalence and impact of migraine, the proposed neurological basis of the condition (and how this is being translated into new and exciting drug therapies), as well as current patient care strategies collated from headache organisations worldwide.

Cushing's Syndrome

Cushing's Syndrome

Cushing’s syndrome shares symptoms such as hypertension, glucose intolerance and obesity with other common conditions – how can you confidently diagnose this rare disorder?

+ 2 more

Load more

Guidelines

Spasticity in under 19s: management

This guideline covers managing spasticity and co-existing motor disorders and their early musculoskeletal complications in children and young people (from birth up to their 19th birthday) with non-progressive brain disorders.

Added 6 years ago

EFNS guidelines on the Clinical Management of Amyotrophic Lateral Sclerosis (MALS) – revised report of an EFNS task force

Objectives: To provide evidence-based or expert recommendations for the diagnosis and management of ALS based on a literature search and the consensus of an expert panel.

Added 7 years ago

Use of antibody testing in nervous system disorders

To evaluate service provision and quality assurance schemes for clinically useful autoantibody tests in neurology.

Added 7 years ago

Search all guidelines for Other hereditary or degenerative neurological disorders
 

Journal articles

Nusinersen: A Treatment for Spinal Muscular Atrophy.

Objective: To review the efficacy and safety of nusinersen (Spinraza) in the treatment of spinal muscular atrophy (SMA).

Added 7 months ago

Is amyotrophic lateral sclerosis/frontotemporal dementia an autophagy disease?

Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are neurodegenerative disorders that share genetic risk factors and pathological hallmarks. Intriguingly, these shared factors result in a high rate of comorbidity of...

Added 1 year ago

Advances, challenges and future directions for stem cell therapy in amyotrophic lateral sclerosis.

Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative condition where loss of motor neurons within the brain and spinal cord leads to muscle atrophy, weakness, paralysis and ultimately death...

Added 1 year ago

Search all journal articles for Other hereditary or degenerative neurological disorders
 

Clinical trials

A Safety, Tolerability, and Efficacy Study of Intracerebroventricular BMN 190 in Pediatric Patients < 18 Years of Age With CLN2 Disease

This Phase 2 open-label, multicenter study will evaluate the safety, tolerability, and efficacy of BMN 190 intracerebroventricular (ICV) administration every other week (qow) for a period of 96 weeks, in patients with CLN2.

Added 1 year ago

A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 Disease

The Phase 1/2 study (190-201) evaluated the efficacy and safety of doses up to 300 mg/every other week (qow) BMN 190 in patients with CLN2. The dose and regimen for this study (190-202) are based on the results of the 190-201 study.

Added 1 year ago

A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA) (CHERISH)

The primary objective of this study is to examine the clinical efficacy of nusinersen (ISIS 396443) administered intrathecally to participants with later-onset Spinal Muscular Atrophy (SMA).

Added 1 year ago

Search all clinical trials for Other hereditary or degenerative neurological disorders
 

CME

Huntington's disease: clinical review

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
2
Registration required
1
Subscription fee
0

Cerebral palsy

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
0
Registration required
1
Subscription fee
0

Motor neurone disease: clinical review

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
1
Registration required
1
Subscription fee
0
Search all CME for Other hereditary or degenerative neurological disorders